Skip to main content
Premium Trial:

Request an Annual Quote

Cytek Biosciences Closes $120M Series D Financing Round

NEW YORK — Flow cytometry instrument developer Cytek Biosciences said on Thursday that it has raised $120 million in a Series D financing round.

The round was led by RA Capital and Hillhouse Capital with participation from OrbiMed and Lyfe Capital.

Cytek said that it will use the funding to expand its global infrastructure, as well as to expand its presence in the cell-analysis market in areas such as immunotherapy, immuno-oncology, and infectious disease.

In conjunction with the round, members of RA Capital and Hillhouse Capital have joined Cytek's board of directors.

In August, Cytek launched its cFluor line of reagents for its Aurora and Northern Lights cytometry systems. About a year ago, the Fremont, California-based company updated the Aurora instrument, which it said can run beyond 40-color panels.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.